Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.74 USD
-0.01 (-1.33%)
Updated Jun 14, 2024 03:58 PM ET
After-Market: $0.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Enveric Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -17.29 | -18.47 | -48.98 | -6.86 | -6.03 |
Depreciation/Amortization & Depletion | 0.41 | 7.89 | 39.36 | 0.41 | 2.27 |
Net Change from Assets/Liabilities | -0.17 | -0.22 | 1.19 | -0.37 | 1.74 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.96 | -6.35 | -3.03 | 2.94 | -0.43 |
Net Cash From Operating Activities | -14.09 | -17.15 | -11.46 | -3.89 | -2.45 |
Property & Equipment | 0.01 | -0.58 | -0.19 | 0.00 | -0.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 3.06 | 0.00 | -0.20 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -0.68 | -0.04 | 0.00 |
Net Cash from Investing Activities | 0.01 | -0.58 | 2.19 | -0.04 | -0.28 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1.05 | 17.22 | 24.90 | 0.00 | 2.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 1.67 | -1.33 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.29 | 0.96 | 0.00 | 3.86 | 0.00 |
Net Cash from Financing Activities | -1.34 | 18.18 | 24.90 | 5.53 | 1.80 |
Effect of Exchange Rate Changes | -0.01 | -0.08 | 0.14 | -0.06 | 0.00 |
Net Change In Cash & Equivalents | -15.44 | 0.37 | 15.78 | 1.53 | -0.94 |
Cash at Beginning of Period | 17.72 | 17.36 | 1.58 | 0.04 | 1.37 |
Cash at End of Period | 2.29 | 17.72 | 17.36 | 1.58 | 0.43 |
Diluted Net EPS | -8.09 | -13.00 | -103.50 | -59.50 | -566.00 |
Fiscal Year End for Enveric Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -2.46 | -17.29 | -13.86 | -11.03 | -4.68 |
Depreciation/Amortization & Depletion | 0.09 | 0.41 | 0.32 | 0.23 | 0.11 |
Net Change from Assets/Liabilities | -0.56 | -0.17 | -0.38 | -0.62 | -0.92 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.33 | 2.96 | 1.57 | 1.83 | 0.35 |
Net Cash From Operating Activities | -2.60 | -14.09 | -12.34 | -9.60 | -5.14 |
Property & Equipment | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.98 | -1.05 | -1.05 | -1.05 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.67 | -0.29 | -0.11 | 0.00 | 0.00 |
Net Cash from Financing Activities | 6.66 | -1.34 | -1.16 | -1.05 | 0.00 |
Effect of Exchange Rate Changes | 0.01 | -0.01 | 0.03 | 0.00 | -0.02 |
Net Change In Cash & Equivalents | 4.07 | -15.44 | -13.46 | -10.64 | -5.16 |
Cash at Beginning of Period | 2.29 | 17.72 | 17.72 | 17.72 | 17.72 |
Cash at End of Period | 6.36 | 2.29 | 4.27 | 7.08 | 12.56 |
Diluted Net EPS | -0.61 | -1.44 | -1.30 | -3.04 | -2.31 |